SAB Biotherapeutics’ (SABS) Buy Rating Reaffirmed at HC Wainwright
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $6.
Craig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)
In a report released yesterday, Albert Lowe from Craig-Hallum maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a ...
来自MSN2 个月
SABS stock touches 52-week low at $2.12 amid market challenges
In a challenging market environment, Big Cypress Acquisition Corp. (SABS) stock has hit a 52-week low, trading at $2.12. While the company has faced headwinds over the past year with a 27% decline ...
SAB BIO Reports Full Year 2024 Operating and Financial Results
On May 21, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) provided clearance for the Company’s investigational new drug (IND) application to proceed with a Phase 1 ...
SAB Biotherapeutics (SABS) to Release Earnings on Thursday
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) is expected to issue its quarterly earnings data before the market opens ...